

CLAIMS

1. A compound having the formula:




(VI),




,

or




wherein –G–H–J is



,

wherein each H and J is independently selected,

or –G–H–J is




,

wherein R_x is selected from CH_2, NH, N($C_{1–8}$ alkyl), S, and O; R_y and R_z are C or CH each independently substituted with one or more F, CH_3, CF_3, OH, or OCH_3; or R_x, R_y, and R_z are each independently selected from CH_2 and CR^aR^b wherein R^a and R^b are taken together to form a $C_{3–7}$ carbocycle;

J' is selected from NH_2, NH($C_{1–8}$ alkyl), N($C_{1–8}$ alkyl)$_2$, NHC(=O)CH_3, NHC(=O)NH_2, NHC(=NH)NH_2, and NHC(=NH)H;

wherein n is 0, 1, or 2;

alternatively, –G–H–J is



wherein R_x is selected from CH_2, NH, N($C_{1–8}$ alkyl), S, and O; R_z is a C or CH, substituted with one or more CH_3 or R_z is CR^aR^b wherein R^a and R^b are taken together to form a $C_{3–7}$ carbocycle, wherein m is 1, 2, or 3;

J' is selected from NH_2, NH($C_{1–8}$ alkyl), N($C_{1–8}$ alkyl)$_2$, NHC(=O)CH_3, NHC(=O)NH_2, NHC(=NH)NH_2, and NHC(=NH)H;

C–B–A–, –D–E–F, and –G–H–J are chemical moieties, wherein

D and G are independently selected from the group consisting of:

(a) a single bond, (b) –($C_{1–8}$ alkyl)– , (c) –($C_{2–8}$ alkenyl)–, (d) –($C_{2–8}$ alkynyl)–, wherein

i) 0–4 carbon atoms in any of (b)–(d) immediately above optionally is replaced by a moiety selected from the group consisting of –O–, –S(O)$_p$–, –NR^6–, –(C=O)–, –S(O)$_p$$NR^6$–, –$NR^6$S(O)$_p$–, and –$NR^6$S(O)$_p$$NR^6$–,

ii) any of (b)–(d) immediately above optionally is substituted with one or more R^5 groups, and

iii) any of (b)–(d) immediately above optionally is substituted with –($C_{1–8}$ alkyl)–R^5 groups;

(e) –O–, (f) –NR^6–, (g) –S(O)$_p$–, (h) –C(O)–, (i) –C(O)O–, (j) –OC(O)–, k) –OC(O)O–, (l) –C(O)NR^6–, (m) –NR^6CO–, (n) –NR^6C(O)NR^6–, (o) –C(=NR^6)–, (p) –C(=NR^6)O–, (q) –OC(=NR^6)–, (r) –C(=NR^6)NR^6–, (s) –NR^6C(=NR^6)–, (t) –C(=S)–, (u) –C(=S)NR^6–, (v) –NR^6C(=S)–, (w) –C(O)S–, (x) –SC(O)–, (y) –OC(=S)–, (z) –C(=S)O–, (aa) –NR^6(CNR^6)NR^6–, (bb) –CR^6R^6C(O)–, (cc) –C(O)NR^6(CR^6R^6)$_t$–, (dd) a 3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(ee) a 3–14 member saturated, unsaturated, or aromatic carbocycle, and

(ff) –$(CR^6R^6)_t$–,

wherein (dd) or (ee) is optionally substituted with one or more R^5 groups;

E and H are independently selected from the group consisting of:

(a) a single bond,

(b) a 3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur,

(c) a 3–14 member saturated, unsaturated, or aromatic carbocycle,

wherein (b) or (c) is optionally substituted with one or more R^5 groups;

(d) –($C_{1–8}$ alkyl)–, (e) –($C_{2–8}$ alkenyl)–, (f) –($C_{2–8}$ alkynyl)–, wherein

i) 0–4 carbon atoms in any of (d)–(f) immediately above optionally is replaced by a moiety selected from the group consisting of –O–, –$S(O)_p$–, –NR^6–, –(C=O)–, –$C(=NR^6)$–, –$S(O)_pNR^6$–, –$NR^6S(O)_p$–, and –$NR^6S(O)_pNR^6$–,

ii) any of (d)–(f) immediately above optionally is substituted with one or more R^5 groups, and

iii) any of (d)–(f) immediately above optionally is substituted with –($C_{1–8}$ alkyl)–R^5 groups;

and (g) –$(CR^6R^6)_t$–,


F and J are independently selected from the group consisting of:






















(a) hydrogen, (c) F, (d) Cl, (e) Br, (f) I, (g) –CF_3, (h) –CN, (i) –N_3 (j) –NO_2, (k) –$NR^6(CR^6R^6)_tR^8$, (l) –OR^8, (m) –$S(O)_p(CR^6R^6)_tR^8$, (n) –$C(O)(CR^6R^6)_tR^8$, (o) –$OC(O)(CR^6R^6)_tR^8$, (p) –$SC(O)(CR^6R^6)_tR^8$, (q) –$C(O)O(CR^6R^6)_tR^8$, (r) –$NR^6C(O)(CR^6R^6)_tR^8$, (s) –$C(O)NR^6(CR^6R^6)_tR^8$, (t) –$C(=NR^6)(CR^6R^6)_tR^8$, (u) –$C(=NNR^6R^6)(CR^6R^6)_tR^8$, (v) –$C(=NNR^6C(O)R^6)(CR^6R^6)_tR^8$, (w) –$C(=NOR^8)(CR^6R^6)_tR^8$, (x) –$NR^6C(O)O(CR^6R^6)_tR^8$, (y) –$OC(O)NR^6(CR^6R^6)_tR^8$, (z) –$NR^6C(O)NR^6(CR^6R^6)_tR^8$, (aa) –$NR^6S(O)_p(CR^6R^6)_tR^8$, (bb) –$S(O)_pNR^6(CR^6R^6)_tR^8$, (cc) –$NR^6S(O)_pNR^6(CR^6R^6)_tR^8$, (dd) –$NR^6R^8$, (ee) –$NR^6(CR^6R^6)R^8$, (ff) –OH, (gg) –$NR^8R^8$, (hh) –$OCH_3$, (ii) –$S(O)_pR^8$, (jj) –




$NC(O)R^8$, (kk) $–NR^6C(NR^6)NR^6R^8$, (ll) a $C_{1–8}$ alkyl group, (mm) a $C_{2–8}$ alkenyl group, (nn) a $C_{2–8}$alkynyl group, (oo) a 3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (pp) a 3–14 member saturated, unsaturated, or aromatic carbocycle, (qq) $–(CR^6R^6)_tNR^6(CR^6R^6)_tR^8$, (rr) $–N[(CR^6R^6)_tR^8][C=O(CR^6R^6)_tR^8]$, (ss) $–(CR^6R^6)_tN[(CR^6R^6)_tR^8][(CR^6R^6)_tR^8]$, (tt) $–(CR^6R^6)_tNR^6(C=O)(CR^6R^6)_tR^8$, (uu) –haloalkyl, (vv) $–C(O)(CR^6)[(CR^6R^6)_tR^8]R^8$, (ww) $–(CR^6R^6)_tC(O)NR^8R^8$, (xx) $–(CR^6R^6)_tC(O)O(CR^6R^6)_tR^8$, (yy) $–NR^6C(O)CR^8R^8R^8$, (zz) $–N[(CR^6R^6)_tR^8]C(O)R^8$, and (aaa) $–S(O)_pNR^8R^8$;


wherein (ll) through (pp) is optionally substituted with one or more R^7 groups;


C–B–A– is selected from the group consisting of:







, and

R^5 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $–CF_3$, (g) –CN, (h) $–N_3$ (i) $–NO_2$, (j) $–NR^6R^6$, (k) $–OR^8$, (l) $–NR^6(CNR^6)NR^6R^6$, (m) $–C_{1–8}$ alkyl, (n) $–C_{2–8}$ alkenyl, (o) $–C_{2–8}$ alkynyl, (p) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic carbocycle), (r) –haloalkyl, (s) $–SR^6$, (t) –3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (u) –3–14 member saturated, unsaturated, or aromatic carbocycle; alternatively, two R^5 groups are taken together to form a carbocycle;

wherein (m) through (r) and (t) through (u) is optionally substituted with one or more R^8;

R^6 is selected from (a) hydrogen, (b) $–C_{1–8}$ alkyl or alternatively two R^6 groups are taken together to form a carbocycle, (c) –haloalkyl, (d) –3–14 member saturated, unsaturated, or aromatic heterocycle

containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (e) –3–14 member saturated, unsaturated, or aromatic carbocycle;
wherein (b) through (e) is optionally substituted with one or more R^8;

R^7 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $–CF_3$, (g) –CN, (h) $–N_3$ (i) $–NO_2$, (j) $–NR^6R^6$, (k) $–OR^6$, (l) $–NR^6(CNR^6)NR^6R^6$, (m) $–C_{1–8}$ alkyl, (n) $–C_{2–8}$ alkenyl, (o) $–C_{2–8}$ alkynyl, (p) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic carbocycle), (r) –haloalkyl, (s) $–NR^6R^8$, (t) $–OR^8$, (u) $–(CR^6R^6)_tNR^6R^8$, (v) $–CR^6R^8R^8$, (w) $–SR^6$, (x) –3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (y) –3–14 member saturated, unsaturated, or aromatic carbocycle, (z) $–(CR^6R^6)_tC(O)NR^8R^8$, (aa) $–S(O)_pR^8$, (bb) $–NR^6C(O)NR^6R^6$, (cc) $–NR^6C(O)R^6$, and (dd) $–C(=NR^6)NR^6R^6$;
wherein (m) through (q) and (x) through (y) are optionally substituted with one or more $R^{9;}$

R^8 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $–CF_3$, (g) –CN, (h) $–N_3$ (i) $–NO_2$, (j) $–NR^6R^9$, (k) $–OR^9$, (l) $–NR^6(CNR^6)NR^6R^6$, (m) $–C_{1–8}$ alkyl, (n) $–C_{2–8}$ alkenyl, (o) $–C_{2–8}$ alkynyl, (p) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic carbocycle), (r) –3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (s) –3–14 member saturated, unsaturated, or aromatic carbocycle, (t) –haloalkyl, (u) $–C(O)(CR^6R^6)_tR^9$, (v) $–SR^6$, (w) $–OC(O)(CR^6R^6)_tR^9$, (x) $–NR^6C(O)NR^6R^9$, (y)$–NR^6C(O)R^9$, (z) $–NR^6(CNR^9)(NR^6R^6)$, (aa) $–ONR^6(CNR^6)NR^6R^6$, (bb) $–C(=NR^9)NR^6R^6$, (cc) $–S(O)_pR^9$, (dd) $–(CR^6R^6)_tC(O)NR^6R^9$, (ee) $–(CR^6R^6)_tOR^9$, and (ff) $–(CR^6R^6)_tNR^6R^9$;
wherein (m) through (s) is optionally substituted with one or more R^9;


R^9 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $–CF_3$, (g) –CN, (h) $–N_3$ (i) $–NO_2$, (j) $–NR^6R^{10}$, (k) $–OR^6$, (l) $–NR^6(CNR^6)NR^6R^6$, (m) $–C(O)(CR^6R^6)_tNR^6R^6$, (n) $–C_{1–8}$ alkyl, (o) $–C_{2–8}$ alkenyl, (p) $–C_{2–8}$ alkynyl, (q) –3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (r) –3–14 member saturated, unsaturated, or aromatic carbocycle, (s) –haloalkyl, (t) $–(CR^6R^6)_tOR^6$, (u) $–O(CR^6R^6)_tNR^6R^{10}$, (v) $–C(O)R^6$, (w) $–SR^6$, (x) $–C(O)OR^{10}$, (y) $–S(O)_pR^6$, (z) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (aa) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic carbocycle), (bb) $–O(CR^6R^6)_tOR^6$, (cc) $–C(=NR^6)NR^6R^6$, (dd) $–ONR^6R^6$, (ee) $–NR^6C(O)NR^6R^6$, (ff) $–O(CR^6R^6)_tOR^6$, (gg) $–NR^6C(O)R^6$, and (hh) $–(CR^6R^6)_tNR^6R^{10}$;
wherein (n) through (r) and (z) through (aa) is optionally substituted with one or more R^{10};

R^{10} is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $–CF_3$, (g) –CN, (h) $–N_3$ (i) $–NO_2$, (j) $–NR^6R^6$, (k) $–OR^6$, (l) $–NR^6(CNR^6)NR^6R^6$, (m) $–C(O)(CR^6R^6)_tNR^6R^6$, (n) $–C_{1–8}$ alkyl, (o) $–C_{2–8}$ alkenyl, (p) $–C_{2–8}$ alkynyl, (q) –3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, (r) –3–14 member saturated, unsaturated, or aromatic carbocycle, (s) –haloalkyl, (t) $–(CR^6R^6)_tOR^6$, (u) $–O(CR^6R^6)_tNR^6R^6$, (v) $–C(O)R^6$, (w) $–SR^6$, (x) $–C(O)OR^6$, (y) $–S(O)_pR^6$, (z) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (aa) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic carbocycle), (bb) $–O(CR^6R^6)_tOR^6$, (cc) $–C(=NR^6)NR^6R^6$, (dd) $–ONR^6R^6$, (ee) $–NR^6C(O)NR^6R^6$, (ff) $–O(CR^6R^6)_tOR^6$, (gg) $–NR^6C(O)R^6$, and (hh) $–(CR^6R^6)_tNR^6R^6$;

wherein either the group –D–E–F or the group –G–H–J is absent, but both –D–E–F and –G–H–J are not simultaneously absent;
p is 0, 1, or 2, and
t is 1, 2, or 3,


or a pharmaceutically acceptable salt, ester, or tautomer thereof.

2. The compound according to Claim 1 having the formula:



or a pharmaceutically acceptable salt, ester, or tautomer thereof.

3. The compound according to Claim 1 having the formula:



or a pharmaceutically acceptable salt, ester, or tautomer thereof.

4. The compound according to Claim 1, wherein G is selected from

(a) a single bond, (b) –($C_{1–8}$ alkyl)–, (c) –($C_{2–8}$ alkenyl)–, (d) –($C_{2–8}$ alkynyl)–, wherein

i) 0–4 carbon atoms in any of (b)–(d) immediately above optionally is replaced by a moiety selected from the group consisting of –O–, –$S(O)_p$–, –NR^6–, –(C=O)–, –$C(=NR^6)$–, –$S(O)_pNR^6$–, –$NR^6S(O)_p$–, and –$NR^6S(O)_pNR^6$–,

ii) any of (b)–(d) immediately above optionally is substituted with one or more R^5 groups, and

iii) any of (b)–(d) immediately above optionally is substituted with –($C_{1–8}$ alkyl)– R^5 groups;

(e) a 3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and

(f) a 3–14 member saturated, unsaturated, or aromatic carbocycle,

wherein (e) or (f) is optionally substituted with one or more R^5 groups;

or a pharmaceutically acceptable salt, ester, or tautomer thereof.

5. The compound according to Claim 1, wherein R^5 is selected from (a) hydrogen, (b) F, (c) Cl, (d) Br, (e) I, (f) $–CF_3$, (g) –CN, (h) $–N_3$ (i) $–NO_2$, (j) $–NH_2$, (k) $–OR^6$, (l) $–NHC(=NH)NH_2$, (m) $–C_{1–8}$ alkyl, (n) $–C_{2–8}$ alkenyl, (o) $–C_{2–8}$ alkynyl, (p) $–(C_{1–8}$ alkyl) –(3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur), (q) $–(C_{1–8}$ alkyl)–(3–14 member saturated, unsaturated, or aromatic carbocycle), (r) –haloalkyl, (s) $–SR^6$, (t) –3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (u) –3–14 member saturated, unsaturated, or aromatic carbocycle; alternatively, two R^5 groups are taken together to form a carbocycle; or a pharmaceutically acceptable salt, ester, or tautomer thereof.

6. The compound according to Claim 1, wherein R^6 is selected from (a) hydrogen, (b) $–C_{1–8}$ alkyl or alternatively two R^6 groups are taken together to form a carbocycle, (c) –haloalkyl, (d) –3–14 member saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and (e) –3–14 member saturated, unsaturated, or aromatic carbocycle; or a pharmaceutically acceptable salt, ester, or tautomer thereof.

7. The compound according to Claim 1, wherein G is selected from

(a) a single bond, (b) $–(C_{1–8}$ alkyl)–, (c) $–(C_{2–8}$ alkenyl)–, (d) $–(C_{2–8}$ alkynyl)–, wherein


i) 0–4 carbon atoms in any of (b)–(d) immediately above optionally is replaced by a moiety selected from the group consisting of –O–, $–S(O)_p–$,$–NR^6–$, –(C=O)–, $–C(=NR^6)–$, $–S(O)_pNR^6–$, $–NR^6S(O)_p–$, and $–NR^6S(O)_pNR^6–$,

























ii) any of (b)–(d) immediately above optionally is substituted with one or more R^5 groups, and







iii) any of (b)–(d) immediately above optionally is substituted with $–(C_{1–8}$ alkyl)–R^5 groups;


wherein p is 0, 1, or 2,

or a pharmaceutically acceptable salt, ester, or tautomer thereof.


8. The compound according to Claim 3, wherein  is selected from:

and 

or –G–H–J is




wherein R_x is selected from CH_2, NH, $N(C_{1–8}$ alkyl), S, and O; R_y and R_z are C or CH each independently substituted with one or more F, CH_3, CF_3, OH, or OCH_3; or R_x, R_y, and R_z are each independently selected from CH_2 and CR^aR^b wherein R^a and R^b are taken together to form a $C_{3–7}$ carbocycle;

J' is selected from NH_2, $NH(C_{1–8}$ alkyl), $N(C_{1–8}$ alkyl$)_2$, $NHC(=O)CH_3$, $NHC(=O)NH_2$, $NHC(=NH)NH_2$, and NHC(=NH)H;

wherein n is 0, 1, or 2;

alternatively, –G–H–J is













wherein R_x is selected from CH_2, NH, $N(C_{1–8}$ alkyl), S, and O; R_z is a C or CH, substituted with one or more CH_3 or R_z is CR^aR^b wherein R^a and R^b are taken together to form a $C_{3–7}$ carbocycle,






wherein m is 1, 2, or 3;







J' is selected from NH_2, $NH(C_{1–8}$ alkyl), $N(C_{1–8}$ alkyl)$_2$, $NHC(=O)CH_3$, $NHC(=O)NH_2$, $NHC(=NH)NH_2$, and NHC(=NH)H; or a pharmaceutically acceptable salt, ester, or tautomer thereof.






9. A compound selected from,





Comp. No.	Structure
392	
393	
396	
400	






402	
440	
442	
460	
528	
529	






543	
544	
557	
558	
575	






576	
578	
579	
592	
595	
598	





603	
604	
606	
614	
615	





627	
638	
639	
641	





642	
643	
651	
656	
657	





658	
659	
660	
664	
667	





669	
671	
672	
674	
675	





676	
681	
685	
686	





689	
690	
691	
694	





695	
696	
707	
708	





714	
715	
718	
729	





730	
731	
732	
733	




738	
740	
741	
748	




749	
750	
751	
752	





753	
754	
763	
765	





774	
776	
777	
781	






782	
783	
792	
793	






794	
795	
798	






811	
812	
818	





832	
833	
858	
859	





868	
869	
870	
888	





889	
890	
891	
903	
904	




908	
909	
916	
917	
919	




920	
921	
938	
941	 





942	
950	
953	
954	




955	
956	
972	
973	




976	
993	
1006	
1007	




1008	
1014	
1016	




1025	
1026	
1030	





1031	
1032	
1033	
1041	





1042	
1055	
1056	





1058	
1070	
1071	






1072	
1073	
1082	





1083	
1084	
1086	






1096	
1133	
1134	
1135	





1145	
1146	
1147	
1192	






1193	
1197	
1198	
1212	





1213	
1234	
1235	
1236	
1237	





1238	
1244	
1269	
1270	




1271	
1368	
1369	
1370	
1421	

1426	
1427	
1441	
1449	

1450	
1464	 
1465	 

1466	
1467	
4000c	
4001c	

4002c	
4003c	
4004c	
4005c	

4006c	
4007c	
4008c	

or a pharmaceutically acceptable salt, ester, or tautomer thereof.

10. A pharmaceutical composition comprising a compound according to Claim 1, or a pharmaceutically acceptable salt, ester, or tautomer thereof, and a pharmaceutically acceptable carrier.

11. A compound according to Claim 1, or a pharmaceutically acceptable salt, ester, or tautomer thereof for use in treatment of a microbial infection in a human or animal.

12. A compound according to Claim 1, or a pharmaceutically acceptable salt, ester, or tautomer thereof, for use in the treatment or reduction of the risk of a microbial infection in a human or animal wherein the microbial infection is selected from the group consisting of:

a skin infection, a Gram positive infection, a Gram negative infection, nosocomial pneumonia, community acquired pneumonia, post–viral pneumonia, hospital acquired pneumonia/ventilator associated pneumonia, a respiratory tract infection, acute pelvic infection, a complicated skin and skin structure infection, a skin and soft tissue infection (SSTI) including uncomplicated skin and soft tissue infections (uSSTI)s and complicated skin and soft tissue infections, an abdominal infection, a complicated intra-abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio–ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin–resistant *Staphylococcus aureus* infection, a vancomycin–resistant *Enterococci* infection, a linezolid–resistant organism infection, a *Bacillus anthracis* infection, a *Francisella tularensis* infection, a *Yersinia pestis* infection, and tuberculosis.

13. The compound for use according to Claim 12, wherein the compound, or a pharmaceutically acceptable salt, ester, or tautomer thereof, is to be administered otically, ophthalmically, nasally, orally, parenterally, intravenously, or topically.

14. Use of a compound according to Claim 1, or a pharmaceutically acceptable salt, ester, or tautomer thereof, in the manufacture of a medicament for the treatment of a microbial infection in a human or animal.

15. Use of a compound according to Claim 1, or a pharmaceutically acceptable salt, ester, or tautomer thereof, in the manufacture of a medicament for the treatment or the reduction of the risk of microbial infection in a human or animal, wherein the microbial infection is selected from the group consisting of:

a skin infection, a Gram positive infection, a Gram negative infection, nosocomial pneumonia, community acquired pneumonia, post–viral pneumonia, hospital acquired pneumonia/ventilator associated pneumonia, a respiratory tract infection, acute pelvic infection, a complicated skin and skin structure infection, a skin and soft tissue infection (SSTI) including uncomplicated skin and soft tissue infections (uSSTI)s and complicated skin and soft tissue infections, an abdominal infection, a complicated intra-abdominal infection, a urinary tract infection, bacteremia, septicemia, endocarditis, an atrio–ventricular shunt infection, a vascular access infection, meningitis, surgical prophylaxis, a peritoneal infection, a bone infection, a joint infection, a methicillin–resistant *Staphylococcus aureus* infection, a vancomycin–resistant *Enterococci* infection, a linezolid–resistant organism infection, a *Bacillus anthracis* infection, a *Francisella tularensis* infection, a *Yersinia pestis* infection, and tuberculosis.

16. The use according to Claim 15, wherein the compound, or a pharmaceutically acceptable salt, ester, or tautomer thereof, is to be administered otically, ophthalmically, nasally, orally, parenterally, intravenously, or topically.